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Abstract
Although apoptosis plays a critical role in molding the CNS into its final appearance and
function, inappropriate activation of this pathway in the aging brain may contribute to
neurodegeneration. In Alzheimer’s disease (AD), an overwhelming body of evidence
supports the activation of apoptosis in general, and caspases specifically as an early event
that may not only contribute to neurodegeneration but also promote the underlying
pathology associated with this disease. Therefore, caspase inhibitors may provide an
effective strategy for treating AD. However, despite the compelling evidence indicating a
role for caspases in disease progression, chronic treatment with caspase inhibitors in animal
models of AD has never been undertaken. In this review the role of caspases in AD will be
addressed, including recent studies utilizing in vivo transgenic mouse models of
tauopathies. In addition, a discussion of the therapeutic value and dangers of targeting
caspase inhibition in the treatment of AD using caspase inhibitors such as Q-VD-OPh will
be evaluated.
Keywords: apoptosis, caspases, Alzheimer’s Disease, tau, beta-amyloid, amyloid precursor protein,
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Overview of Alzheimer’s Disease
Recent statistics in the United States regarding Alzheimer’s disease (AD) are alarming: 5.3 million people have AD
with a new case diagnosed every 70 seconds and AD is currently the sixth leading cause of death [1]. AD is a
progressive neurodegenerative disorder characterized by confusion, disturbances in short-term memory and
cognitive impairment. These early symptoms of AD may be overlooked because they resemble signs of natural
aging. As the disease progresses, the symptoms gradually worsen until patients lose the ability to feed themselves,
speak, recognize people and memory becomes almost non-existent. In addition, during the advanced stages of
dementia, the impact on the lives of patients and their caregivers is enormous.
Pathologically, AD is a progressive neurodegenerative disorder characterized by significant losses of neurons and
synapses [2]. Diagnosis is based on the extent of accumulation of senile plaques, neurofibrillary tangles (NFTs), and
neuron loss [3]. NFTs consist of paired helical filaments (PHF) resulting from the hyper-phosphorylation of the
microtubule-binding protein tau. As a microtubule-associated protein, tau plays an essential role in maintaining
microtubule stability similar to ties along railroad tracks. However, in AD neuronal tau is aberrantly phosphorylated
and proteolyzed resulting in an impairment of the normal functions of tau [4, 5]. Besides NFTs, the other
troublemakers are senile plaques composed principally of extracellular amyloid- (A ) depositions. A is formed
following sequential cleavage of the amyloid precursor protein (APP) by two proteases termed - and -secretases.
Following generation, A self-aggregates into insoluble -sheet structures leading to the formation of extracellular
plaques. The deposition of A is an early event in the pathogenesis of AD that precedes the formation of NFTs and
collectively is referred to as the “beta-amyloid hypothesis” [6]. More recently, the beta-amyloid hypothesis has been
extended by suggesting that A - oligomers, due to their central neuropathologic role, are the major causative
species for the development of AD [7]. The extension of the beta-amyloid hypothesis to include A oligomers is
based at least in part on the poor correlation between the number of senile plaques and cognitive decline [8]. Figure
1b depicts the characteristic pathology associated with AD, with an abundance of both plaques and tangles present
in one representative brain region, the hippocampus. Interestingly, a smattering of tangles can also be observed in
the age-matched non-demented control subject (arrow, Fig. 1a). The finding of NFTs in non-demented aging
subjects is a well-documented finding (for example, see [9]), and suggests that the presence of a small number of
NFTs in vulnerable brain regions doesn’t not necessary imply neurodegeneration or disease. Although the presence
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of both plaques and tangles is a central feature associated with AD, the link connecting these two hallmark
pathologies has remained elusive. Recent evidence suggests that caspase activation and cleavage of tau may link
plaques and tangles in AD.
Caspase activation and cleavage of tau in the AD brain
Our interest in the role of caspases in Alzheimer’s began almost 10 years ago when we began investigating
apoptosis as a cell death mechanism in the AD brain. At the time there was support for apoptosis as a major celldeath pathway in the AD brain [10], however, this was greatly disputed because the major technique to detect
apoptosis, TUNEL labeling, was deemed nonspecific [11]. Therefore, we sought to examine a role for apoptosis in
the AD brain utilizing caspase-cleavage site-directed antibodies. In this approach, antibodies are directed towards
the active fragments of caspases or neoepitope regions of caspase substrates following cleavage. This approach was
first employed by Yang el al. who, using a site-directed antibody to caspasecleaved actin, was able to demonstrate
convincingly the activation of apoptotic pathways in the AD brain [12]. This was followed by a comprehensive
study by Gervais et al., in which a site-directed caspase-cleavage antibody to APP demonstrated labeling in the AD
brain and suggested that not only was APP a substrate for caspases but cleavage may facilitate the further production
of the toxic A fragment [13]. Based on these studies, we applied the same approach to design a specific sitedirected antibody to fodrin, a major cytoskeletal protein expressed in neurons [14]. Application of this antibody
showed widespread caspase-cleaved fodrin in the AD brain [15]. An interesting outcome from that study was the
apparent correlation between caspase-cleaved fodrin and NFTs [15]. It was concluded that perhaps there was a link
between caspase activation and the formation of NFTs in the AD brain. Another piece of evidence suggesting that
caspases may link A to NFTs in AD was the identification that tau is a major substrate for caspase cleavage, in
vitro [16]. Canu et al. were able to show that there were three potential caspase cleavage sites within tau, and based
on this study, we designed a caspase-cleavage site-directed antibody to the amino-terminal site within tau. Following
characterization of this antibody, we were able to demonstrate immunolabeling of this antibody in the AD brain that
was absent in age-matched nondemented control subjects [17]. This was the first demonstration of the presence of
caspase-cleaved tau in AD. Following this study, we developed a hypothesis in which A triggers the activation of
caspases leading to proteolysis of tau and the NFT formation[18].
Shortly thereafter, two studies largely confirmed our hypothesis by demonstrating that the caspase cleavage of tau is
an early event in NFT evolution, and links A to NFT formation in the AD brain [19, 20]. Both studies relied
heavily on data obtained using identical site-directed antibodies to the C-terminal caspase-cleavage site within tau
located at amino acid residue D421. Both studies supported a general role for caspase-3 as being the major
executioner protease involved in cleaving tau at this C-terminal site. In addition to caspase-3, strong evidence for
caspase-6 and the cleavage of tau in the AD brain has been demonstrated [21], suggesting the cooperation of
multiple members of the caspase family in the proteolysis of tau. Importantly, the use of postmortem human AD
tissue in these studies makes it difficult to determine a direct relationship between the caspase-cleavage of tau and
the formation of NFTs. Figure 2 summarizes the data supporting a role for caspase activation as being one link
between A and NFT formation in the AD brain.
More recently, transgenic mice studies have provide additional evidence that caspases play a proximal role in
promoting tangle formation in AD. We utilized the 3xTg-AD mice developed by Oddo et al. to examine more
directly the role for caspases in tangle formation. 3xTg-AD mice sequentially form A
alterations including hyperphosphorylation that closely models what occurs in the human AD brain [22, 23]. We
generated 3xTg-AD mice that overexpress the anti-apoptotic protein, Bcl-2, specifically in neurons of the CNS and
aged the mice accordingly before behavioral and pathological examination. It was determined that overexpression of
Bcl-2 prevented caspase activation and cleavage of tau, limited the degree of tau hyperphosphorylation, and
improved spatial memory [24]. Even more convincing then this study, are the recent studies coming out of Bradley
Hyman’s group using multiphoton microscopy, a technique that allows one to detect caspase activation in the living
brain and follow this activation over several days. Using this powerful technique, Spires-Jones et al. were able to
detect active caspases within tangle-bearing neurons in the rTg4510 mouse model of tauopathy [25]. They have been
able to extend these findings by showing that even though caspases are activated with NFT-bearing neurons, these
neurons do not immediately die, but exhibit significant loss of membrane integrity as indicated by the presence
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of propidium iodide labeling [26]. Taken together, these studies employing animal models of AD provide strong
experimental support for a role in caspases in the etiology associated with AD, and thus, are potential therapeutic
targets for the treatment of this disease.
Caspases as Therapeutic Targets in the Treatment of AD
The potential for caspase inhibitors as therapeutic agents is not unique to AD. Indeed, for many years caspase
inhibitors such as N-benzyloxycarbonyl-Val-Ala-Asp fluoromethyl-ketone (Z-VAD) were being investigated for the
treatment of a number of neurodegenerative disorders including amyotrophic lateral sclerosis (ALS) [27],
Huntington’s disease [28], Parkinson’s disease (PD) [29], and finally acute neurologic diseases including ischemia
or traumatic injury (for review, see [30]). Unfortunately, clinical development of Z-VAD was discontinued
following the recognition that metabolism of Z-VAD produces liver damage following the production of the toxic
compound, fluoroacetate [31].
Following the disappointment of Z-VAD, a number of other caspase inhibitors have been developed with the goal in
mind of being safer and more selective. Quinolyl-valyl-Omethylaspartyl-[- 2, 6-difluorophenoxy]-methyl ketone (QVD-OPh) is a newer, third-generation broad-spectrum caspase inhibitor that has potential as a therapeutic compound
[32]. Q-VD-OPh appears to be far superior to Z-VAD in many respects including greater potency, selectivity,
stability and cell permeability [32]. Q-VD-OPh also appears to be less toxic than Z-VAD even at very high
concentrations [33]. Most importantly, Q-VD-OPh appears to be able to cross the blood-brain barrier, which is
always a central issue when developing a drug for treatment of a CNS disorder. Evidence for neuroprotection
included studies demonstrating efficacy of Q-VDOPh in animal models of Parkinson’s, Huntington’s disease and
stroke [34, 35]. Therefore, QVD-OPh would seem to be an ideal candidate to test whether pharmacological
inhibition of caspases in vivo can prevent the pathology associated with AD. The critical next step is to test directly
whether Q-VD-OPh prevents neurodegeneration or other aspects of pathology using animal models of AD.
Another promising compound that is currently under evaluation is minocycline, a second-generation tetracycline. In
comparison to Q-VD-OPh, minocycline is much further along as an investigational drug for the treatment of
neurodegenerative disorders and in some cases human clinical trials have begun. For example, minocycline is
currently being tested in a Phase II PD clinical trial as well as a Phase I/II clinical trial for spinal cord injury (for a
recent review, see [36]). In addition, recently a Phase III trail involving minocycline as a therapeutic agent for the
treatment of ALS was completed. Unfortunately, the results of the trial were negative as the authors found that
patients on minocycline declined at a more rapid rate than the placebo group [37]. These results are disappointing
and certainly will have implications for potential future clinical trials of minocycline in AD. Nonetheless, there is
ample data to suggest minocycline may be a suitable treatment option for AD. In one study by Choi et al., the
authors reported that minocycline administration improved behavior deficits in A infused rats [38]. Minocycline
also has been shown to improve behavioral deficits while reducing the level of microglial activation in a mouse of
model cerebral microvascular amyloid, although there was no apparent reduction in A
another study using transgenic mice harboring the human APPsw and V717F mutations, treatment with minocycline
had a positive effect on reducing microglial activation but did not attenuate A
APP mice [40]. Younger mice faired better, exhibiting improved behavioral and microglial suppression following
minocycline treatment [40]. Finally, a recent study showed that in primary cortical neurons minocycline prevented
A -induced death, caspase-3 activation, and reduced the levels of caspase-cleaved tau [41]. The same authors
showed that in vivo treatment of transgenic mice overexpressing human tau with minocycline reduced levels of tau
phosphorylation and tau cleavage by caspase-3 [41]. Taken together, these studies support a preventative effect of
minocycline on caspase activation, pathological changes to tau and the inflammation associated with AD with little
effect on A deposition. This suggests that the mechanism of action of minocycline may lie downstream to A
production and deposition.
Mechanistically, current data suggests minocycline inhibits apoptosis by preventing the release of cytochrome c
from mitochondria and subsequent caspase-3 activation [42, 43], although how minocycline is actually
accomplishing this feat is presently unknown. Minocycline also exhibits strong anti-inflammatory actions
particularly in preventing reactive microgliosis [44, 45] a key feature that has been associated with AD [46].
Therefore, minocycline would seem an ideal compound to be tested in the treatment of AD based partly on its
putative mechanisms of action. Table 1 summarizes the similarities and differences between Q-VD-OPh and
minocycline with regards to their potential as therapeutic agents for the treatment of AD.
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Possible toxicities associated with caspase inhibitors as treatment compounds for AD
An obvious point of concern of utilizing caspase inhibitors such as Q-VD-OPh in the treatment of AD are potential
toxicities related to the inhibition of apoptosis in other cell types. Chronic administration of any caspase inhibitor for
a time period exceeding 14 days has never been reported in any animal model or in vivo disease system. Clearly, one
might predict the deleterious effects of a non-selective caspase inhibitor, given the important role of caspases in
overall tissue homeostasis. However, based on available evidence, Q-VD-OPh and other caspase inhibitors may
have a more limited toxicity profile than predicted. First, Chauvier et al., found that after acute treatment of Q-VDOPh in mice, all organs were normal suggesting a lack of toxicity [33]. Second, the caspase inhibitor IDN-6556,
which shares structural similarities with Q-VD-OPh, was reported to be safe and well tolerated in humans (up to 10
mg/kg/infusion for a single dose) in a phase I clinical trial [47]. This was a 14-day study in which there were no
apparent drug-related adverse events. Third, the potential for a lack of toxicity by Q-VD-OPh could be predicted
based on the fact that caspase inhibitors cannot block any caspase-independent cell death pathways. Similar to IDN6556, minocycline has a proven track record for safety in a number of clinical trials involving humans. For example,
treatment with minocycline in Phase I clinical trials for ALS and PD has been successfully completed with little
toxicity noted (reviewed in [36]). However, in a recent Phase III trial, patients on minocycline declined more
quickly than those on placebo [37]. In addition, a Phase II trial for PD indicated a decrease tolerability of
minocycline in the treatment group [48]. It should be noted that differences in toxicity between minocycline and QVD-OPh may be expected if one considers the multiplicity of putative actions of minocycline versus Q-VD-OPh,
which is extremely selective for only inhibiting caspases. In sum, the potential for toxicity and untoward side effects
with caspase inhibitors is an obvious concern. Until comprehensive studies with caspase inhibitors, such as Q-VDOPh are carried out in animal models of AD one can only speculate on the relative efficacy versus toxicity that may
occur following chronic treatment.
Conclusions
Mounting evidence suggests the involvement of caspases in the disease process associated with AD. The activation
of caspases may be responsible for the neurodegeneration associated with AD and several recent studies have
suggested that caspases may also play a role in promoting the disease mechanisms associated with this disease.
Thus, caspase activation and cleavage of critical cellular proteins associated with AD pathology may facilitate both
the production of A as well as the formation of NFTs. Because the activation of caspases in AD may be a proximal
event that is not just associated with neurodegeneration, caspases are potential therapeutic targets for the treatment
of this disorder. Presently, there are only a few FDA-approved medications available for patients afflicted with AD
and these medications are palliative in nature. Although there are numerous strategies under development that
involve the beta-amyloid hypothesis, it is still not known whether these strategies will positively impact the disease.
Given the recent phase III clinical trial failures involving the beta-amyloid hypothesis [49], a prudent approach to
developing therapeutics for AD should be aimed at other potential targets. Over a decade of research has supported a
role for the activation of caspases in the AD brain, and recent studies has indicated an involvement in this pathway
in promoting the pathology underlying this disease. However, to date, studies testing the potential of anti-apoptotic
compounds have yet to be realized. This may be partly due to real concerns related to potential side effects
associated with the chronic treatment of apoptotic inhibitors including most importantly, the potential for tumor
formation. Two compounds, minocycline and Q-VD-OPh, seem ideal candidates to test in animal models of AD.
Until studies in animal models of AD are carried out, we will never know whether the risk/reward associated with
caspase inhibitors such as Q-VD-OPh are worthy of future drug development for the treatment of AD. With the
number of Americans with Alzheimer’s expected to triple by the middle of the century [1], the risk of testing
apoptotic inhibitors as a treatment strategy seems well worth the effort.
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Table 1. Comparisons of Q-VD-OPh and minocycline as potential compounds for the treatment of
Alzheimer’s disease
Compound
Q-VD-OPh

Minocycline

Mechanism of
Action
Broad pan-caspase inhibitor
with no cross-reactivity to
other proteases including
cathepsins, calpains, or
granzyme B.

1) Anti-apoptotic actions;
both caspase-dependent and
independent
2) Anti-inflammatory
actions; suppression of
microglia and inhibition of T
lymphocytes
3) Inhibition of p38 MAPK
activation in microglia

Advantages

Disadvantages

Proven caspase inhibitor with
very select mechanism of
action. Great improvements
over older compounds such as
Z-VAD including potency,
toxicity, and stability.

Transport into the CNS,
bioavailability, and
selectivity for specific
caspases could be
problematic. Selection
between “good” versus
“bad” apoptosis. Cost
prohibitive for long-term
study (3-24 months). Little
in vivo data available
compared to minocycline.
Limited testing in animal
models of AD.
Multiplicity of actions
may lead to untoward
side effects. Recent ALS
Phase III clinical trial with
minocycline was negative.
Clinical trials in PD and
Huntington’s disease have
revealed potential safety
concerns in humans.

Orally available and
demonstrated effectiveness in a
number of other model
degenerative diseases. Proven
tract record for safety in
humans. Potential dual
functions as apoptotic inhibitor
and anti-inflammatory agent
may beneficial in treating AD.
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Figure Legends
Fig. 1 Senile plaques and neurofibrillary tangles are the hallmarks of Alzheimer’s disease
Representative staining from an age-matched control subject (a) or an individual with severe AD (b). In AD,
widespread labeling of senile plaques composed principally of the A
(brown staining) along with numerous
NFTs composed of truncated and hyperphosphorylated tau (blue staining) can be seen in the entorhinal cortex.
Often, one can observe a few NFTs along with neuropil threads in the absence of A
-matched
controls. However, the difference clearly being the number of NFTs observed as compared to the AD brain.
Fig. 2 Putative pathway of NFT formation and neuronal cell death in Alzheimer’s disease.
According to the A
synthesis following cleavage by
APP molecule leads
to all subsequent downstream events. In one scenario, A
oligomers leading to the production of
reactive oxygen species (ROS), oxidative stress and eventually cell death [50, 51]. Alternatively or simultaneously,
A
activation through the initiation of apoptosis. The activation of caspases leads to the
cleavage of critical cellular proteins including actin, fodrin and most importantly tau. The cleavage of these proteins
may result in the breakdown of the cytoskeleton while the cleavage of tau may facilitate its hyperphosphorylation,
leading to further instability in the cytoskeleton. Disruption of the microtubule network may also lead to impaired
axonal transport and eventually neuronal cell death. Not shown is the fact that caspases have also been shown to
cleave APP and thus, facilitate the further production of A
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